Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05555550 · ClinicalTrials.gov registry record · Early Phase 1
Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
A Early Phase 1 study of Glioma and Low Grade Glioma, sponsored by Children's Hospital of Philadelphia.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05555550: Recruiting Early Phase 1 study of Glioma and Low Grade Glioma, sponsored by Children's Hospital of Philadelphia.
NCT05555550 is a Early Phase 1 study of Glioma and Low Grade Glioma that is actively recruiting participants, run by Children's Hospital of Philadelphia. The registered enrollment target is 30 participants, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05555550, a Early Phase 1 study of Glioma and Low Grade Glioma, is actively recruiting participants, sponsored by Children's Hospital of Philadelphia.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if 18F-Fluciclovine (Axumin®) is useful and safe in the management of children with Low Grade Gliomas (LGG). Imaging with 18F-Fluciclovine PET-MRI will be performed prior to initiation of therapy for LGG, and then 3 months, and 1 year after starting therapy. Changes in 18F-Fluciclovine uptake will be compared to changes in MRI measurements at 3 months and 1 year as compared to baseline.
Primary Outcome
To identify change in the standardized uptake value (SUV) parameters (SUVmax, SUVpeak) for the 18F-Fluciclovine PET scan
Conditions Studied
Interventions
- DRUG 18F-Fluciclovine
Study Locations (1)
Pennsylvania
- The Children s Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-12-29 |
| Est. Completion | 2027-09 |
| Phase | Early Phase 1 |
What NCT05555550 shows while recruiting
NCT05555550 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (86% lower).
The record links to 5 conditions, with Glioma appearing as the primary indexed condition, and to 1 intervention - of which 18F-Fluciclovine is the first listed.
NCT05555550 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05555550 about?
NCT05555550 is a clinical study titled "Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG". The purpose of this study is to see if 18F-Fluciclovine (Axumin®) is useful and safe in the management of children with Low Grade Gliomas (LGG). Imaging with 18F-Fluciclovine PET-MRI will be performed prior to initiation of therapy for LGG, and then 3 months, and 1 year after starting therapy. Chang...
What is the current status of trial NCT05555550?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2025-12-29. Estimated completion is 2027-09.
What conditions does trial NCT05555550 study?
This clinical trial studies the following conditions: Glioma, Low Grade Glioma, Glioma, Malignant, Low Grade Glioma of Brain, Glioma Intracranial.
What interventions are being tested in trial NCT05555550?
The interventions under investigation include: 18F-Fluciclovine (DRUG).
Who is sponsoring clinical trial NCT05555550?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05555550 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05555550's enrollment target sits among peer trials
30 53rd of 87 higher than 31 of 87 other Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease
RECRUITING · Early Phase 1
-
18F-Fluciclovine PET-MRI in High-grade Glioma
RECRUITING · Early Phase 1
-
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
RECRUITING · Early Phase 1
-
Contrast Enhanced Ultrasound in Neurosurgery to Improve Glioma Visualization and Border Demarcation
RECRUITING · Early Phase 1
-
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
ACTIVE NOT RECRUITING · Early Phase 1
-
AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
ACTIVE NOT RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI